Across an array of neurologic diseases, there is often a lack of objective diagnostic testing. In the case of Parkinson’s disease and related disorders, autopsy studies suggest an over 30% misdiagnosis rate particularly early in the disease course in part because of this lack of easily accessible and reliable diagnostics.
Dr. Christopher Gibbons was interviewed by Dr. Jason Crowell last week on the Neurology®
podcast about a recently published paper he co-authored titled “Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.”
Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy
A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders, Christopher Gibbons and Roy Freeman (and other academic colleagues), presented the first-ever data suggesting the possibility that measurable pathological markers in the skin can reveal distinct biological characteristics to help separate one type of synucleinopathy from another.
As CND Life Sciences continues to experience growth, launch new diagnostic tests, and expand its impact in the neurodegenerative disease space, the company can’t help but be future-focused. And one way CND invests in the future is by growing talent through an internship program that offers invaluable work experience to its participants.
Neurodegenerative diseases like Parkinson’s and dementias continue to represent some of the most significant threats to human health and the healthcare system at large.
Clinicians often encounter patients who do not fit neatly into one diagnostic bucket. These cases may present with symptoms of more than one disease, or they may have symptoms
that only partially fulfill diagnostic criteria.
The mission of the clinical laboratory at CND Life Sciences—to provide timely and accurate test results that aid in the diagnosis and treatment of patients—may not seem different from that of other
labs, but behind this mission you’ll find a unique working environment where the quality of personal interactions and the culture are as important as the quality of the test results.
CND Life Sciences is pleased to announce the launch of the Syn-One Clinician Network, a directory of some of the hundreds of neurologists who are using the Syn-One Test® to aid in the diagnosis of Parkinson’s disease and other neurological disorders.
Over 2 million people in the US have a synucleinopathy, and 100,000 are diagnosed every year. Many more patients go undiagnosed because there hasn’t been a simple clinical method available
to make a diagnosis.
Be sure to stop by CND Life Sciences’ booth at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, September 21-24 in Nashville, TN. Learn about the complexities of diagnosing autonomic disorders and small fiber neuropathies and how CND’s Syn-One Test® and Small-Fiber Dx™ can help.